NNVC NanoViricides Inc
Company Analysis
Latest News
NanoViricides Bets on an Oral Ebola Drug in the World's Second-Largest Outbreak — But Can a $29 Million Company Deliver?
Shares of NanoViricides surged 10.7% to $1.16 on September 15, bucking a 2.11% decline in the broader biotech sector, after the company announced it expects to...
🟢 NanoViricides is trading 10.69% up today as Phase II Ebola trial begins next week
NanoViricides is trading 10.69% up now at $1.16 after announcing its Phase II NV-387 oral-gummy trial for Ebola is scheduled to begin next week in the...
🟢 NanoViricides is trading 5.2% up today after announcing Phase II trial begins next week
NanoViricides is trading 5.2% up at $1.10 after announcing on September 15, 2026, that its Phase II trial of NV-387 oral gummies for Ebola is scheduled to...
NanoViricides launches Phase II Ebola trial, testing first oral gummy treatment
NanoViricides Inc. will launch a Phase II clinical trial for its oral Ebola drug, NV-387, next week in the Democratic Republic of Congo. The study takes place...
🟢 NanoViricides is trading 6.86% up today with no clear catalyst identified
NanoViricides is trading 6.86% up at $1.06, reversing from its September 11 close of $1.02; no clear company-specific catalyst was identified. - No new...
🟢 NanoViricides is trading 7.14% up in pre-market; catalyst unclear
NanoViricides is trading at $1.20 (+7.14%) in pre-market on September 8, 2026, with the catalyst unclear. - No fresh company announcement dated September 7 or...
🟢 NanoViricides is trading 5% up today amid 2.75% biotech-sector gains
NanoViricides is trading 5.37% up now at $1.27, apparently driven by biotech-sector momentum rather than a company-specific catalyst. - No newly identified...
🟢 NanoViricides is trading 5.65% up today after announcing Phase II measles trial preparations
NanoViricides is trading $1.31 (+5.65%) after announcing preparations for a Phase II clinical-trial protocol for NV-387 as a measles treatment. - On August...
🟢 NanoViricides rises 5.3% — Biotech Sector Continues Upward Trend on Strong Momentum
With Biotech (XBI) up 2.0%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🟢 NanoViricides is trading 6.6% up in pre-market after DRC approval for NV-387 Phase II trial
NanoViricides is trading 6.6% up at $1.45 after receiving Democratic Republic of Congo regulatory approval on August 10, 2026, to begin a Phase II trial of...
🟢 NanoViricides is trading 5.7% up in pre-market after DRC approval to begin NV-387 Ebola trial
NanoViricides is trading higher in pre-market at $1.48 (+5.71%) after receiving Democratic Republic of Congo regulatory approval on August 10, 2026, to begin a...
NanoViricides wins DRC approval for oral Ebola gummies, fighting record outbreak
NanoViricides Inc. received regulatory approval in the Democratic Republic of Congo (DRC) to begin a Phase II clinical trial for NV-387. This study evaluates...
🔴 NanoViricides is trading 6.5% down in pre-market — no clear catalyst identified
NanoViricides is trading 6.51% down now at $1.33 after no company-specific announcement was identified for August 8–10, 2026. - The investor-relations page...
🔴 NanoViricides is trading 6.3% down today with no clear company-specific catalyst found
NanoViricides is trading at $1.35 (-6.25%) in after-hours sessions following a close of $1.44 on August 5, 2026, as no major company-specific news or earnings...
🟢 NanoViricides is trading 8.5% up today on continued momentum with no fresh news catalyst
NanoViricides is trading 8.5% up at $1.61 as the stock extends a recent rebound from late-July lows despite a lack of fresh company-specific news or analyst...
🟢 NanoViricides is trading 5.2% up today on no clear company-specific news or catalysts
NanoViricides is trading at $1.63 (+5.16%) in after-hours trading with no company-specific announcements, earnings releases, or late-breaking news found to...
🔴 NanoViricides is trading 5.3% down today amid broader biotech weakness and risk-off sentiment
NanoViricides is trading at $1.52 (-5.28%) as the stock faces downward pressure in the absence of company-specific catalysts. • The decline appears consistent...
NanoViricides Funds Phase II Ebola Trial, Advancing Oral Gummy Treatment
NanoViricides secured financing for a Phase II clinical trial of its oral Ebola drug, NV-387. The company is awaiting regulatory approval from ACOREP to begin...
🟢 NanoViricides is trading 5.8% up today on momentum follow-through despite no fresh news
NanoViricides is trading 5.8% up today at $1.63 on momentum follow-through and high-volatility trading, despite a lack of fresh company-specific news. • No...
🟢 NanoViricides Inc is trading 8.11% up
NNVC is trading at $1.60, up 8.11%.